Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients [Yahoo! Finance]
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: Yahoo! Finance
Artelo Biosciences Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology First patient enrollment anticipated in Q2 2026 SOLANA BEACH, Calif., March 18, 2026 (GLOBE NEWSWIRE) Artelo Biosciences, Inc. (Nasdaq: ARTL) a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has entered into a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust (BHSCT). The study will evaluate the effects of Artelo's peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension. Funding for the study is being provided by Glaucoma UK and the HSC R&D Division , two respected organizations supporting innovative health and social care research to improve patient outcomes. Glaucoma is a lead
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 TreatmentsGlobeNewswire
- Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline StrengthGlobeNewswire
- Artelo Biosciences Inc [CNN]CNN
- Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical StudyGlobeNewswire
- Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma PatientsGlobeNewswire
ARTL
Sec Filings
- 3/26/26 - Form EFFECT
- 3/24/26 - Form S-1
- 3/24/26 - Form S-1/A
- ARTL's page on the SEC website